Comparative Pharmacology
Head-to-head clinical analysis: EXENATIDE SYNTHETIC versus MOUNJARO AUTOINJECTOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXENATIDE SYNTHETIC versus MOUNJARO AUTOINJECTOR.
EXENATIDE SYNTHETIC vs MOUNJARO (AUTOINJECTOR)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Exenatide synthetic is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the incretin hormone GLP-1, enhancing glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon secretion, slowing gastric emptying, and promoting satiety.
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It increases glucose-dependent insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Subcutaneously 5 mcg twice daily within 60 minutes before morning and evening meals; may increase to 10 mcg twice daily after 1 month.
Subcutaneously once weekly; initial dose 2.5 mg for 4 weeks, then increase to 5 mg for 4 weeks, then 7.5 mg, 10 mg, 12.5 mg, and 15 mg as tolerated; maximum 15 mg weekly.
None Documented
None Documented
Terminal elimination half-life is 2.4 hours for subcutaneous administration, supporting twice-daily dosing.
Terminal elimination half-life ~5 days (117 hours), supporting once-weekly dosing.
Primarily renal via glomerular filtration and proteolytic degradation; approximately 30% of the dose is excreted unchanged in urine, with the remainder as metabolites in urine and feces.
Renal: negligible; Fecal: primarily via biliary elimination as intact peptide; total clearance ~0.056 L/h.
Category A/B
Category C
GLP-1 Receptor Agonist
Dual GIP/GLP-1 Receptor Agonist